On an earnings call yesterday, Novartis announced that the FDA has sent a complete response letter for their product pegfilgrastim, biosimilar to Neulesta.
Novartis and its generics unit, Sandoz, have been hailed as trailblazers in the biosimilar market in the United States, especially after the approval of Zarxio, biosimilar to Amgen. However, on an earnings call yesterday, Novartis announced that the FDA has sent a complete response letter for their product pegfilgrastim, biosimilar to Neulesta.
According to Reuters, Vasant Narasimhan, head of development at Novartis Pharmaceuticals said that the company had received the complete response letter in June. STAT News reported that Novartis told analysts on the call that the situation was complex and that they are working with the agency to address the remaining questions.
Novartis had filed the Biologics License Application (BLA) for pegfilgrastim late last year, about 8 months after Zarxio was approved by the FDA. A pegylated form of recombinant human granulocyte colony-stimulating factor, Amgen’s Neulesta is approved for use to reduce the incidence of infections in patients with non-myeloid malignancies who are receiving myelosuppressive anticancer agents. To seek approval for the same indications for it’s biosimilar, Sandoz submitted results from 2 pivotal clinical trials: a drug distribution trial in healthy volunteers and 2 comparative efficacy trials and safety studies in breast cancer patients.
Sandoz has been faring quite well on its other biosimilar products: it’s biosimilar to etanercept (Enbrel) was unanimously supported by an FDA advisory committee, and it’s biosimilar to rituximab (MabThera in the EU) was accepted for regulatory review by the European Medicines Agency.
Amgen, meanwhile, will have a breather for a short while. Neulasta earned $4.72 billion in sales last year, with a major chunk, $3.89 billion, from sales in the United States.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More